Richard Y. Zhang

发表

Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials

P. Park, M. Essex, S. Upadhyay, 2013, Expert opinion on drug safety.

Efficacy of low-dose celecoxib in patients with acute pain.

B. Schachtel, D. McCabe, M. Berger, 2011, The journal of pain : official journal of the American Pain Society.

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques

B. Wyman, D. M. van der Heijde, T. Fuerst, 2016, Annals of the rheumatic diseases.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

R. Moots, P. Emery, D. Mevorach, 2017, The Lancet.

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

C. Wouters, Y. Zhang, E. Alexeeva, 2021, The Lancet.

Impact of donepezil treatment for Alzheimer's disease on caregiver time

B. Winblad, A. Wimo, T. McRae, 2004, Current medical research and opinion.

A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

Roy W Jones, H. Soininen, D. Aarsland, 2004, International journal of geriatric psychiatry.

Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease

H. Brodaty, Stavros J. Baloyannis, P. Cras, 2004, Drugs & aging.

An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

B. Winblad, H. Soininen, A. Wimo, 2002, Dementia and Geriatric Cognitive Disorders.

Safety and Tolerability of Donepezil at Doses up to 20 mg/day

R. Doody, J. Corey-Bloom, R. Schindler, 2008, Drugs & aging.

Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis

Timothy W. Smith, M. Dougados, J. Greenberg, 2020, Advances in Therapy.

Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs

M. Essex, S. Mallen, Richard Y. Zhang, 2011, Current medical research and opinion.

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

Yoshiya Tanaka, H. Valdez, T. Stock, 2018, Rheumatology.

Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease

J. Cummings, O. Lopez, S. Gauthier, 2010, International Psychogeriatrics.

Defining Treatment Response to Donepezil in Alzheimer’s Disease

A. Burns, E. Schwam, C. Perdomo, 2008, Drugs & aging.

Predicting cognitive decline in Alzheimer's disease: An integrated analysis

J. Cummings, O. Lopez, G. Waldemar, 2010, Alzheimer's & Dementia.

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

K. Thirunavukkarasu, W. Bensen, J. Kaine, 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

A. Zauber, M. Bertagnolli, B. Levin, 2012, Clinical therapeutics.

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.

J. Cummings, T. McRae, Richard Y. Zhang, 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.

J. Cummings, O. Lopez, G. Waldemar, 2010, Journal of Alzheimer's disease : JAD.

Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17

T. McRae, I. Lott, G. Spiridigliozzi, 2010, American journal of medical genetics. Part A.

Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease

Roy W Jones, J. Cummings, O. Lopez, 2011, International journal of geriatric psychiatry.

Rates of Cognitive Change in Alzheimer Disease: Observations Across a Decade of Placebo-controlled Clinical Trials With Donepezil

Gunhild Waldemar, Elias Schwam, Roy W. Jones, 2009, Alzheimer disease and associated disorders.

A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease

Christy Chuang-Stein, Andrew C Leon, A. Leon, 2011, Clinical trials.

3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy

B. Winblad, H. Soininen, A. Wimo, 2006, Dementia and Geriatric Cognitive Disorders.

Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease

Roy W Jones, J. Cummings, O. Lopez, 2011, Trials.